UPDATE: Jefferies Initiates ABM Industries at Buy on Expected Realignment Benefits

In a report published on Wednesday, Jefferies analyst Dan Dolev initiated coverage on ABM Industries (NYSE: ABM ) at Buy with a price target of $28. In the report, Jefferies noted, "Over the next 12-24 months we expect rising healthcare costs to boost roll-ups with vertical expansion and lower commercial